Canine Dilated Cardiomyopathy: Long-Term Follow-up of Gene Therapy
Okay, I’ve extracted and summarized the key information from the provided text. Hear’s a breakdown:
Main Idea:
Researchers are exploring VEGF-B167 gene therapy as a potential treatment for canine dilated cardiomyopathy (DCM). The initial research suggests it may slow disease progression.
Key Points:
Problem: DCM is a serious heart disease in dogs,especially large breeds,leading to heart failure and sudden death. The cause is frequently enough unknown.
Current Treatment Limitations: Current treatments only manage symptoms after heart failure develops and don’t stop the underlying heart muscle deterioration.
new Approach: Researchers are investigating VEGF-B167 gene therapy.
Method: The study uses adeno-associated viral vectors (AAV) to deliver the VEGF-B167 gene directly into the heart via the coronary artery.
Potential Benefit: The therapy may* slow the progression of DCM.
In essence,the text introduces a promising new avenue of research for a devastating canine disease.
VEGF-B167 Gene Therapy for Canine Dilated Cardiomyopathy: A Promising New Approach
Table of Contents
- VEGF-B167 Gene Therapy for Canine Dilated Cardiomyopathy: A Promising New Approach
- What is Canine Dilated Cardiomyopathy (DCM)?
- What are the Current Treatment Options for Canine DCM?
- What is VEGF-B167 Gene Therapy?
- How Does VEGF-B167 Gene Therapy Work?
- What are the Potential Benefits of VEGF-B167 Gene Therapy for Dogs wiht DCM?
- What Different Dosages Have Been Studied?
- What are the Risks and Side Effects of VEGF-B167 Gene Therapy?
- How Does VEGF-B167 Gene Therapy differ from Intramyocardial Injection of the gene?
- Where Can I Find More Data on VEGF-B167 Gene Therapy?
- Key Takeaways: VEGF-B167 Gene Therapy Research for canine DCM
- Disclaimer
Dilated cardiomyopathy (DCM) is a serious heart condition affecting many dogs, particularly certain large breeds. While current treatments focus on managing the symptoms after heart failure develops, they don’t address the underlying deterioration of the heart muscle. Recent research explores a novel approach: VEGF-B167 gene therapy. Here’s what you need to know about this exciting development.
What is Canine Dilated Cardiomyopathy (DCM)?
DCM is a disease of the heart muscle that causes it to become enlarged and weakened. This weakening impairs the heart’s ability to pump blood effectively, eventually leading to heart failure and potentially sudden death.the exact cause of DCM is often unknown, but genetics, nutrition, and infections are believed to play a role.
What are the Current Treatment Options for Canine DCM?
Currently,treatment for DCM focuses on managing the symptoms of heart failure. These treatments typically include:
Medications: Diuretics to reduce fluid buildup,ACE inhibitors to help blood vessels relax,and other drugs to improve heart function.
Dietary Management: Special diets low in sodium can also help manage fluid retention.
Unluckily, these treatments primarily address the consequences of DCM and do not halt or reverse the disease’s progression.
What is VEGF-B167 Gene Therapy?
VEGF-B167 gene therapy is an experimental approach that aims to slow the progression of DCM by directly targeting the heart muscle. It involves delivering the VEGF-B167 gene into the heart cells.
How Does VEGF-B167 Gene Therapy Work?
Researchers use adeno-associated viral vectors (AAV) to deliver the VEGF-B167 gene into the heart.The process involves the following:
- AAV as a Delivery Vehicle: A harmless virus (AAV) is modified to carry the VEGF-B167 gene.
- Direct Delivery: The AAV,carrying the gene are delivered directly into the heart muscle cells via the coronary artery.
- Gene Expression: Once inside the heart cells, the VEGF-B167 gene is expressed, leading to the production of the VEGF-B167 protein.
The VEGF-B167 protein is believed to have a protective effect on heart cells.
What are the Potential Benefits of VEGF-B167 Gene Therapy for Dogs wiht DCM?
early research suggests that VEGF-B167 gene therapy may slow the progression of DCM. Studies in dogs with pacing-induced heart failure showed that VEGF-B167 gene therapy,delivered via intracoronary infusion of adeno-associated virus serotype 9 (AAV),delayed the development of heart failure.( [3] Intracoronary Cytoprotective Gene therapy: A Study of VEGF-B167 in a …VEGF-B 167 Gene Therapy in Dilated Cardiomyopathy. Intracoronary infusion of adeno-associated virus serotype 9 (AAV)-vascular endothelial growth factor (VEGF)-B delays development of pacing-induced heart failure.)
This is a significant finding,as it suggests the possibility of intervening before the onset of severe heart failure. One study even showed while control-group dogs developed overt congestive heart failure, while VEGF-B-transduced dogs were still in relatively good condition. ([2] Intramyocardial VEGF-B167 Gene Delivery Delays the Progression Towards …Methods and Results. AAV-9-carried VEGF-B 167 cDNA (10 12 genome copies) was injected into the myocardium of chronically instrumented dogs developing tachypacing-induced dilated cardiomyopathy. After 4 weeks of pacing, green fluorescent protein-transduced dogs (AAV-control, n=8) were in overt congestive heart failure, whereas the VEGF-B-transduced (AAV-VEGF-B, n=8) were still in a well)
What Different Dosages Have Been Studied?
Research has explored different dosages of AAV9-VEGF-B167 administered via intracoronary infusion:
1 x 1013 genome copies of VEGF-B under the CMV promoter
2 x 1013 genome copies of VEGF-B under the CMV promoter
4 x 1013 genome copies of VEGF-B under the ANF promoter ([1]Dose-dependency and Effectiveness of Cardiac Gene Therapy With Vegf-b …Methods. Nineteen chronically instrumented dogs were subjected to high-frequency cardiac pacing for 4 weeks to induce heart failure and were divided into 3 groups receiving intracoronary infusion of AAV9-VEGF-B167 as follows: 1) 10^13 VEGF-B under the control of the spontaneously active CMV promoter (n=10), 2) 2×10^13 CMV-VEGF-B (n=5), 3) 4×10^13 of VEGF-B controlled by the ANF promoter that )
Note: Further research is needed to determine the optimal dosage and promoter for VEGF-B167 gene therapy.
What are the Risks and Side Effects of VEGF-B167 Gene Therapy?
As gene therapy is still relatively new, it’s critically important to acknowledge potential risks and side effects. While the adeno-associated viral vectors (AAV) used are generally considered safe, there are possibilities of:
Immune Response: The body may recognize the AAV as foreign and mount an immune response.
Off-Target Effects: The gene may be delivered to unintended cells or tissues.
Extensive research is needed to fully assess the safety profile of VEGF-B167 gene therapy in dogs.
How Does VEGF-B167 Gene Therapy differ from Intramyocardial Injection of the gene?
One study of intramyocardial injection of AAV-9-carried VEGF-B 167 cDNA (10 12 genome copies) into the myocardium of dogs also showed positive impacts in the progression of DCM.([2] Intramyocardial VEGF-B167 Gene Delivery Delays the Progression Towards…Methods and Results. AAV-9-carried VEGF-B 167 cDNA (10 12 genome copies) was injected into the myocardium of chronically instrumented dogs developing tachypacing-induced dilated cardiomyopathy. After 4 weeks of pacing, green fluorescent protein-transduced dogs (AAV-control, n=8) were in overt congestive heart failure, whereas the VEGF-B-transduced (AAV-VEGF-B, n=8) were still in a well)
Where Can I Find More Data on VEGF-B167 Gene Therapy?
Consult with your veterinarian to discuss the potential benefits and risks of enrolling your pet in a clinical trial.
Key Takeaways: VEGF-B167 Gene Therapy Research for canine DCM
| Feature | Description |
| ——————- | ———————————————————————————————————————————————————————————————————————————– |
| Main Idea | VEGF-B167 gene therapy shows promise as a potential treatment to slow the progression of canine dilated cardiomyopathy (DCM). |
| Problem | DCM is a severe heart disease in dogs, often leading to heart failure and sudden death, frequently with an unknown cause. |
| current Limits | Current treatments for DCM primarily manage symptoms after heart failure develops, without addressing the underlying disease. |
| New approach | Researchers are exploring VEGF-B167 gene therapy as a way to intervene before the onset of severe heart failure. |
| Method | Uses adeno-associated viral vectors (AAV) to deliver the VEGF-B167 gene directly into the heart.|
| Potential | May slow the progression of DCM; studies have shown that VEGF-B-transduced dogs appeared to resist congestive heart failure when compared to control dogs with induced DCM. |
| Dosages Studied | AAV9-VEGF-B167 administered via intracoronary infusion at: 1 x 1013,2 x 1013,and 4 x 1013 genome copies of VEGF-B |
Disclaimer
This article provides information about ongoing research and should not be taken as medical advice. Consult with your veterinarian for personalized guidance regarding your dog’s health.*